title: Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents.
abstract: Prostate cancer (PCa) is the second-leading cause of cancer deaths among men in the around the world. Understanding the biology of PCa is essential to the development of novel therapeutic strategies, in order to prevent this disease. However, after PCa make metastases, chemotherapy plays an extremely important role. With the pass of the time, PCa cell lines become resistant to the current anti-PCa drugs. For this reason, there is a necessity to develop new anti-PCa agents with the ability to be active against several PCa cell lines. The present work is an effort to overcome this problem. We introduce here the first multi-target approach for the design and prediction of anti-PCa agents against several cell lines. Here, a fragment-based QSAR model was developed. The model had a sensitivity of 88.36% and specificity 89.81% in training series. Also, the model showed 94.06% and 92.92% for sensitivity and specificity, respectively. Some fragments were extracted from the molecules and their contributions to anti-PCa activity were calculated. Several fragments were identified as potential substructural features responsible of anti-PCa activity and new molecular entities designed from fragments with positive contributions were suggested as possible anti-PCa agents.
authors.affiliation: REQUIMTE/Department of Chemistry and Biochemistry, University of Porto, 4169-007 Porto, Portugal. alejspivanovich@gmail.com
authors.forename: Alejandro
authors.initials: A
authors.lastname: Speck-Planche
authors.forename: Valeria V
authors.initials: VV
authors.lastname: Kleandrova
authors.forename: Feng
authors.initials: F
authors.lastname: Luan
authors.forename: M Natália D S
authors.initials: MN
authors.lastname: Cordeiro
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D016002:Discriminant Analysis; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D021281:Quantitative Structure-Activity Relationship; D012372:ROC Curve; D012680:Sensitivity and Specificity
chemical_list: D000970:Antineoplastic Agents